Top

Published in:

09-07-2022 | Respiratory Microbiota | IM - COMMENTARY

The unsolved mystery of MEFV variants variable expressivity in Familial Mediterranean Fever

Authors: Alessandro Stella, Piero Portincasa

Published in: Internal and Emergency Medicine | Issue 5/2022

Excerpt

Familial Mediterranean Fever (FMF) is the most common and best-known hereditary monogenic recurrent fever syndrome [1]. FMF is an autoinflammatory disorder caused by mutations in the MEFV gene which encodes for the pyrin (marenostrin) protein. Pyrin plays a crucial role in the cell response to several damage- and pathogen-associated molecular patterns (DAMPs and PAMPs, respectively). Via its interaction with the apoptosis-associated speck-like protein containing a CARD (ASC or PYCARD) and procaspase-1, pyrin promotes the release of pro-inflammatory cytokines, namely interleukin (IL)-1b and IL-18 [2]. Although traditionally considered an autosomal recessive disorder, FMF cases associated with a single MEFV mutation or with apparently dominant transmission are increasingly recognized [2‐6]. In addition, FMF shows a strikingly unique prevalence with most patients’ clusters identified in countries bordering the Mediterranean basin, hence its name. Indeed, the FMF prevalence has been calculated as high as 1 in 400/500 in Anatolia and Armenia, 1 in 1000 in the rest of Turkey and in Israel and frequent in other Middle East countries, such as Lebanon, Syria, Jordan, and Iran [7]. In Italy, although no formal epidemiological studies have been performed, FMF has an estimated prevalence ranging from 1/2000 to 1/10000, therefore considered a rare disease (renderPdf.spring (salute.gov.it)). …

Portincasa P, Scaccianoce G, Palasciano G (2013) Familial Mediterranean fever: a fascinating model of inherited autoinflammatory disorder. Eur J Clin Invest 43(12):1314–1327. https://doi.org/10.1111/eci.12170CrossRefPubMed

Fukushima Y, Obara K, Hirata H, Sugiyama K, Fukuda T, Takabe K (2013) Three Japanese patients (mother and two children) with familial Mediterranean fever associated with compound heterozygosity for L110P/E148Q/M694I and an autosomal true dominant inheritance pattern. Asian Pac J Allergy Immunol 31(4):325–329. https://doi.org/10.12932/AP0244.31.4.2013CrossRefPubMed

Stoffels M, Szperl A, Simon A, Netea MG, Plantinga TS, van Deuren M, Kamphuis S, Lachmann HJ, Cuppen E, Kloosterman WP, Frenkel J, van Diemen CC, Wijmenga C, van Gijn M, van der Meer JW (2014) MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Ann Rheum Dis 73(2):455–461. https://doi.org/10.1136/annrheumdis-2012-202580CrossRefPubMed

Procopio V, Manti S, Bianco G, Conti G, Romeo A, Maimone F, Arrigo T, Cutrupi MC, Salpietro C, Cuppari C (2018) Genotype-phenotype correlation in FMF patients: a “non classic” recessive autosomal or “atypical” dominant autosomal inheritance? Gene 641:279–286. https://doi.org/10.1016/j.gene.2017.10.068CrossRefPubMed

Stella A, Cortellessa F, Scaccianoce G, Pivetta B, Settimo E, Portincasa P (2019) Familial Mediterranean fever: breaking all the (genetic) rules. Rheumatology 58(3):463–467. https://doi.org/10.1093/rheumatology/key328CrossRefPubMed

Rowczenio DM, Youngstein T, Trojer H, Omoyinmi E, Baginska A, Brogan P, Papadopoulou C, Rezk T, Hawkins PN, Lachmann HJ (2020) British kindred with dominant FMF associated with high incidence of AA amyloidosis caused by novel MEFV variant, and a review of the literature. Rheumatology 59(3):554–558. https://doi.org/10.1093/rheumatology/kez334CrossRefPubMed

Ben-Chetrit E, Touitou I (2009) Familial Mediterranean Fever in the world. Arthritis Rheum 61(10):1447–1453. https://doi.org/10.1002/art.24458CrossRefPubMed

Kasifoglu T, Bilge SY, Sari I, Solmaz D, Senel S, Emmungil H, Kilic L, Oner SY, Yildiz F, Yilmaz S, Bakirli DE, Tufan MA, Yilmaz S, Yazisiz V, Pehlivan Y, Bes C, Cetin GY, Erten S, Gonullu E, Temel T, Sahin F, Akar S, Aksu K, Kalyoncu U, Direskeneli H, Erken E, Kisacik B, Sayarlioglu M, Korkmaz C (2014) Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. Rheumatology 53(4):741–745. https://doi.org/10.1093/rheumatology/ket400CrossRefPubMed

Balci-Peynircioglu B, Kaya-Akca U, Arici ZS, Avci E, Akkaya-Ulum ZY, Karadag O, Kalyoncu U, Bilginer Y, Yilmaz E, Ozen S (2020) Comorbidities in familial Mediterranean fever: analysis of 2000 genetically confirmed patients. Rheumatology 59(6):1372–1380. https://doi.org/10.1093/rheumatology/kez410CrossRefPubMed

10.

Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885. https://doi.org/10.1002/art.1780401023CrossRefPubMed

11.

La Regina M, Nucera G, Diaco M, Procopio A, Gasbarrini G, Notarnicola C, Kone-Paut I, Touitou I, Manna R (2003) Familial Mediterranean fever is no longer a rare disease in Italy. Eur J Hum Genet 11(1):50–56. https://doi.org/10.1038/sj.ejhg.5200916CrossRefPubMed

12.

Ben-Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet 351(9103):659–664CrossRef

13.

Cekin N, Akyurek ME, Pinarbasi E, Ozen F (2017) MEFV mutations and their relation to major clinical symptoms of Familial Mediterranean Fever. Gene 626:9–13. https://doi.org/10.1016/j.gene.2017.05.013CrossRefPubMed

14.

Papadopoulos VP, Giaglis S, Mitroulis I, Ritis K (2008) The population genetics of familial Mediterranean fever: a meta-analysis study. Ann Hum Genet 72(Pt 6):752–761. https://doi.org/10.1111/j.1469-1809.2008.00471.xCrossRefPubMed

15.

Gangemi S, Manti S, Procopio V, Casciaro M, Di Salvo E, Cutrupi M, Ganci G, Salpietro C, Chimenz R, Cuppari C (2018) Lack of clear and univocal genotype-phenotype correlation in familial Mediterranean fever patients: a systematic review. Clin Genet 94(1):81–94. https://doi.org/10.1111/cge.13223CrossRefPubMed

16.

Koshy R, Sivadas A, Scaria V (2018) Genetic epidemiology of familial Mediterranean fever through integrative analysis of whole genome and exome sequences from Middle East and North Africa. Clin Genet 93(1):92–102. https://doi.org/10.1111/cge.13070CrossRefPubMed

17.

Aydin O, Egeli BH, Ozdogan H, Ugurlu S (2022) Late-onset familial Mediterranean fever: single-center experience and literature review. Intern Emerg Med. https://doi.org/10.1007/s11739-021-02912-8CrossRefPubMed

18.

Ozen S, Aktay N, Lainka E, Duzova A, Bakkaloglu A, Kallinich T (2009) Disease severity in children and adolescents with familial Mediterranean fever: a comparative study to explore environmental effects on a monogenic disease. Ann Rheum Dis 68(2):246–248. https://doi.org/10.1136/ard.2008.092031CrossRefPubMed

19.

Giese A, Ornek A, Kilic L, Kurucay M, Sendur SN, Lainka E, Henning BF (2013) Disease severity in adult patients of Turkish ancestry with familial Mediterranean fever living in Germany or Turkey. Does the country of residence affect the course of the disease? J Clin Rheumatol 19(5):246–251. https://doi.org/10.1097/RHU.0b013e31829ce005CrossRefPubMed

20.

Eyal O, Shinar Y, Pras M, Pras E (2020) Familial Mediterranean fever: Penetrance of the p.[Met694Val];[Glu148Gln] and p.[Met694Val];[=] genotypes. Hum Mutat 41(11):1866–1870. https://doi.org/10.1002/humu.24090CrossRefPubMed

21.

Tirosh I, Yacobi Y, Vivante A, Barel O, Ben-Moshe Y, Erez Granat O, Spielman S, Semo Oz R, Shinar Y, Gerstein M (2021) Clinical significance of E148Q heterozygous variant in paediatric familial Mediterranean fever. Rheumatology 60(11):5447–5451. https://doi.org/10.1093/rheumatology/keab128CrossRefPubMed

22.

Atoyan S, Hayrapetyan H, Yeghiazaryan A, Ben-Chetrit E, Sarkisian T (2020) Is the country of living important in the phenotypic expression of E148Q mutation? The Armenian experience. Clin Exp Rheumatol 127(5):124–125

23.

Fujikura K (2015) Global epidemiology of Familial Mediterranean fever mutations using population exome sequences. Mol Genet Genomic Med 3(4):272–282. https://doi.org/10.1002/mgg3.140CrossRefPubMedPubMedCentral

24.

Ricci P, Stella A, Settimo E, Passerini F, Minerva F, Belfiore A, Palmieri VO, Pugliese S, Scaccianoce G, Portincasa P (2019) The grandfather’s fever. Clin Rheumatol. https://doi.org/10.1007/s10067-019-04741-9CrossRefPubMed

25.

Van Gorp H, Huang L, Saavedra P, Vuylsteke M, Asaoka T, Prencipe G, Insalaco A, Ogunjimi B, Jeyaratnam J, Cataldo I, Jacques P, Vermaelen K, Dullaers M, Joos R, Sabato V, Stella A, Frenkel J, De Benedetti F, Dehoorne J, Haerynck F, Calamita G, Portincasa P, Lamkanfi M (2020) Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2019-216701CrossRefPubMed

26.

Magnotti F, Malsot T, Georgin-Lavialle S, Abbas F, Martin A, Belot A, Fauter M, Rabilloud M, Gerfaud-Valentin M, Seve P, Duquesne A, Hot A, Durupt S, Savey L, Giurgea I, Grateau G, Henry T, Jamilloux Y (2021) Fast diagnostic test for familial Mediterranean fever based on a kinase inhibitor. Ann Rheum Dis 80(1):128–132. https://doi.org/10.1136/annrheumdis-2020-218366CrossRefPubMed

27.

Honda Y, Maeda Y, Izawa K, Shiba T, Tanaka T, Nakaseko H, Nishimura K, Mukoyama H, Isa-Nishitani M, Miyamoto T, Nihira H, Shibata H, Hiejima E, Ohara O, Takita J, Yasumi T, Nishikomori R (2021) Rapid flow cytometry-based assay for the functional classification of MEFV variants. J Clin Immunol 41(6):1187–1197. https://doi.org/10.1007/s10875-021-01021-7CrossRefPubMed

28.

Cazeneuve C, Ajrapetyan H, Papin S, Roudot-Thoraval F, Genevieve D, Mndjoyan E, Papazian M, Sarkisian A, Babloyan A, Boissier B, Duquesnoy P, Kouyoumdjian JC, Girodon-Boulandet E, Grateau G, Sarkisian T, Amselem S (2000) Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet 67(5):1136–1143PubMedPubMedCentral

29.

Atoyan S, Hayrapetyan H, Sarkisian T, Ben-Chetrit E (2016) MEFV and SAA1 genotype associations with clinical features of familial Mediterranean fever and amyloidosis in Armenia. Clin Exp Rheumatol 34(102):72–76PubMed

30.

Kriegshauser G, Hayrapetyan H, Atoyan S, Oberkanins C, Sarkisian T (2021) Serum amyloid A1 genotype associates with adult-onset familial Mediterranean fever in patients homozygous for mutation M694V. Rheumatology 60(1):441–444. https://doi.org/10.1093/rheumatology/keaa452CrossRefPubMed

31.

Sharma D, Malik A, Balakrishnan A, Malireddi RKS, Kanneganti TD (2020) RIPK3 promotes Mefv expression and pyrin inflammasome activation via modulation of mTOR signaling. J Immunol 205(10):2778–2785. https://doi.org/10.4049/jimmunol.2000244CrossRefPubMed

32.

Umar M, Megarbane A, Shan J, Syed N, Chouery E, Aliyev E, Jithesh P, Temanni R, Mansour I, Chouchane L, Ismail Chouchane A (2020) Genome sequencing unveils mutational landscape of the familial Mediterranean fever: potential implications of IL33/ST2 signalling. J Cell Mol Med 24(19):11294–11306. https://doi.org/10.1111/jcmm.15701CrossRefPubMedPubMedCentral

33.

Accetturo M, D’Uggento AM, Portincasa P, Stella A (2020) Improvement of MEFV gene variants classification to aid treatment decision making in familial Mediterranean fever. Rheumatology 59(4):754–761. https://doi.org/10.1093/rheumatology/kez332CrossRefPubMed

34.

Verrecchia E, Sicignano LL, La Regina M, Nucera G, Patisso I, Cerrito L, Montalto M, Gasbarrini A, Manna R (2017) Small intestinal bacterial overgrowth affects the responsiveness to colchicine in familial Mediterranean fever. Mediators Inflamm 2017:7461426. https://doi.org/10.1155/2017/7461426CrossRefPubMedPubMedCentral

35.

Ktsoyan ZA, Mkrtchyan MS, Zakharyan MK, Mnatsakanyan AA, Arakelova KA, Gevorgyan ZU, Sedrakyan AM, Hovhannisyan AI, Arakelyan AA, Aminov RI (2016) Systemic concentrations of short chain fatty acids are elevated in salmonellosis and exacerbation of familial Mediterranean fever. Front Microbiol 7:776. https://doi.org/10.3389/fmicb.2016.00776CrossRefPubMedPubMedCentral

36.

Ktsoyan ZA, Beloborodova NV, Sedrakyan AM, Osipov GA, Khachatryan ZA, Kelly D, Manukyan GP, Arakelova KA, Hovhannisyan AI, Olenin AY, Arakelyan AA, Ghazaryan KA, Aminov RI (2010) Profiles of microbial fatty acids in the human metabolome are disease-specific. Front Microbiol 1:148. https://doi.org/10.3389/fmicb.2010.00148CrossRefPubMed

37.

Deshayes S, Fellahi S, Bastard JP, Launay JM, Callebert J, Fraisse T, Buob D, Boffa JJ, Giurgea I, Dupont C, Jegou S, Straube M, Karras A, Aouba A, Grateau G, Sokol H, Georgin-Lavialle S (2019) Specific changes in faecal microbiota are associated with familial Mediterranean fever. Ann Rheum Dis 78(10):1398–1404. https://doi.org/10.1136/annrheumdis-2019-215258CrossRefPubMed

38.

Ozen S, Lutz H, Rivera V, Reiff A, Batu E, Anderson E, Garcia MS, Aldrovandi G, Akbaba T, Pazarbasi İ (2021) Paediatric rheumatology Microbiome is not linked to clinical disease severity of familial Mediterranean fever in an international cohort of children. Clin Exp Rheumatol 39(132):S102–S108CrossRef

39.

Sayan M, Mossman BT (2016) The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases. Part Fibre Toxicol 13(1):51. https://doi.org/10.1186/s12989-016-0162-4CrossRefPubMedPubMedCentral

Title: The unsolved mystery of MEFV variants variable expressivity in Familial Mediterranean Fever
Authors: Alessandro Stella
Piero Portincasa
Publication date: 09-07-2022
Publisher: Springer International Publishing
Keywords: Respiratory Microbiota
Familial Mediterranean Fever
Published in: Internal and Emergency Medicine / Issue 5/2022
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-022-03027-4

Editorial Expression of Concern: Breaking the diagnosis: ankylosing spondylitis evidenced by cervical fracture following spine manipulation

Emergency Medicine
Editorial Expression of Concern

Superficial cervical plexus block in Emergency Departments: rationale for its use in incision and drainage of neck skin abscesses

Incision
CE - Clinical Notes

Late-onset familial mediterranean fever: single-center experience and literature review

Colchicine
IM - ORIGINAL

Guidelines for the appropriate choice of fluid therapy for resuscitation of critically ill patients

Central Nervous System Trauma
CE - LETTER TO THE EDITOR

Drug-related falls and thraumatic brain injury in very old patients: antithrombotic drugs as new potential culpruit factors

Direct Oral Anticoagulant
IM-COMMENTARY

Correction to: Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research

Open Access
Emergency Medicine
Correction

Keynote webinar | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Excerpt

Please log in to get access to this content